Strategy Asset Managers LLC Invests $576,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Strategy Asset Managers LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 548 shares of the biopharmaceutical company’s stock, valued at approximately $576,000.

Other large investors have also recently bought and sold shares of the company. SteelPeak Wealth LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 173.0% in the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after buying an additional 692 shares in the last quarter. Atria Investments Inc boosted its stake in Regeneron Pharmaceuticals by 12.2% in the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after acquiring an additional 941 shares in the last quarter. Mizuho Securities USA LLC grew its holdings in shares of Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after purchasing an additional 51,162 shares during the last quarter. Tri Locum Partners LP increased its position in shares of Regeneron Pharmaceuticals by 104.5% during the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after purchasing an additional 8,949 shares in the last quarter. Finally, Tidal Investments LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 16.8% in the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after purchasing an additional 711 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $743.35 on Thursday. The firm has a market capitalization of $81.69 billion, a price-to-earnings ratio of 18.40, a price-to-earnings-growth ratio of 2.81 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business’s 50 day simple moving average is $961.76 and its 200-day simple moving average is $1,030.14. Regeneron Pharmaceuticals, Inc. has a 12 month low of $736.01 and a 12 month high of $1,211.20.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 7.48% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research analyst reports. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Leerink Partners restated a “market perform” rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.